Aspargo Labs, Inc., a pharmaceutical company commercializing a highly absorbent oral suspension spray technology, has appointed Sam Backenroth as CFO. This strategic hire strengthens the company’s executive team as it advances its corporate growth and commercial expansion plans.

Backenroth brings nearly 20 years of senior financial and strategic leadership experience across the biotechnology sector. He has served as CFO for multiple public and private companies in therapeutic areas including ophthalmology, neurology, immunology, and oncology. His expertise spans capital markets transactions, public company reporting, investor engagement, and building financial and governance infrastructure to support commercialization, operational scaling, and long-term shareholder value.

Michael Demurjian, CEO of Aspargo, said: “Sam has repeatedly demonstrated the ability to position companies for the expectations and rigor of the public markets. He brings deep expertise building institutional-grade financial infrastructure while maintaining strategic flexibility. His long-standing relationships within the investment banking and institutional investor communities, combined with his disciplined approach to financial execution and commercial preparation, will be highly valuable as we execute on both our near-term priorities and Aspargo’s long-term growth objectives.”

Throughout his career, Backenroth has partnered closely with boards and executive teams to align financial and corporate strategy with capital planning and external engagement through key corporate milestones. At Aspargo, he will oversee financial planning, capital strategy, and external communications to support U.S. and European product launches, operational scaling, and new product development initiatives.

Backenroth added: “I’m excited to be joining Aspargo at a pivotal moment in its growth. This platform has the potential to bring best-in-class products to patients at scale, and I look forward to translating that potential into sustainable growth while driving innovation and long-term value for all stakeholders.”

The appointment highlights Aspargo’s ongoing focus on strengthening leadership, governance, and financial foundation to support future opportunities.